Table Graph
   

tocilizumab - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.67, 1.23]< 136%17 studies (17/-)73.3 %some concernlow moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %NAnot evaluable crucial-
deaths 0.88 [0.76, 1.04]< 119%24 studies (24/-)93.7 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.08 [0.73, 1.59]< 156%5 studies (5/-)34.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.76 [0.56, 1.05]< 116%5 studies (5/-)95.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.26 [1.04, 1.52]> 136%5 studies (5/-)99.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %NAnot evaluable important-
death or ventilation 0.83 [0.72, 0.96]< 117%7 studies (7/-)99.4 %some concernnot evaluable moderateimportant-
hospital discharge 1.06 [0.91, 1.23]> 10%3 studies (3/-)75.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.85 [0.61, 1.17]< 10%6 studies (6/-)84.6 %some concernserious moderateimportant-
ICU admission 0.96 [0.54, 1.71]< 156%4 studies (4/-)55.4 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.91 [0.72, 1.15]< 10%7 studies (7/-)78.5 %some concernserious moderateimportant-
adverse events 1.57 [0.96, 2.58]< 169%5 studies (5/-)3.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons